Jørgen Gram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jørgen Gram has a total of 198 co-authors. Here are the top co-authors by number of shared publications:
- Jørgen Jespersen
Unit for Thrombosis Research, Institute of Public Health, University of Southern Denmark
74 shared publications - Johannes Jakobsen Sidelmann
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark
40 shared publications - Else-Marie Bladbjerg
Department of Regional Health Research, University of Southern Denmark, Denmark
14 shared publications - Anna-Marie Bloch Münster
Unit for Thrombosis Research Esbjerg Hospital—University Hospital of Southern Denmark Esbjerg Denmark
12 shared publications C. Kluft
12 shared publicationsCornelis Kluft
11 shared publications
Latest Publications
- 1 August 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (8) , 1078-1084
Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndrome
Introduction Polycystic ovary syndrome (PCOS) is characterized by increased central fat mass (CFM), hyper-inflammation, and hemostatic alterations; the risk of cardiovascular disease may also be increased. Reduced fibrin lysability is a risk factor for cardiovascular disease. The present study assessed fibrin lysability in women with PCOS and controls of similar age and body mass index. Material and methods Ninety women with PCOS and 35 controls of comparable age and body mass index were included. Hemostatic markers (fibrin lysability, fibrinogen, coagulation factor XIII, plasminogen, plasminogen activator inhibitor 1 [PAI-1], plasmin inhibitor, thrombin activatable fibrinolysis inhibitor (TAFI), D-dimer), C-reactive protein (CRP), body mass index, waist-to-hip ratio, CFM determined by Dual-energy X-ray absorptiometry scan, and sex hormones (testosterone estradiol, and sex hormone binding globulin) were determined. Results TAFI and CRP were higher in women with PCOS, than controls. In women with PCOS, fibrin lysability correlated with CFM, waist-to-hip ratio, CRP, fibrinogen, and all hemostatic variables (P <= .004) except TAFI and D-dimer. CFM correlated with fibrinogen, CRP, coagulation factor XIII, waist-to-hip ratio, plasminogen, PAI-1, plasmin inhibitor, and TAFI (P < .02). In controls, fibrin lysability correlated with CFM, fibrinogen, coagulation factor XIII, and plasmin inhibitor (P <= .02). CFM correlated with PAI-1, plasmin inhibitor, coagulation factor XIII, fibrinogen, and CRP (P <= .05). Stepwise regression analysis revealed that fibrin lysability was associated with CFM, fibrinogen and CRP in women with PCOS (r(2) = .46, P <= .001), but only with CFM in controls (r(2) = .28, P < .001). Conclusions Fibrin lysability was comparable in women with PCOS and controls. Fibrin lysability was associated with CFM and hyper-inflammation in women with PCOS, but only with CFM in controls. These findings suggest that obese women with PCOS and augmented inflammation could have an increased risk of cardiovascular disease.
- 1 August 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (8) , 1078-1084
Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndrome
Introduction Polycystic ovary syndrome (PCOS) is characterized by increased central fat mass (CFM), hyper-inflammation, and hemostatic alterations; the risk of cardiovascular disease may also be increased. Reduced fibrin lysability is a risk factor for cardiovascular disease. The present study assessed fibrin lysability in women with PCOS and controls of similar age and body mass index. Material and methods Ninety women with PCOS and 35 controls of comparable age and body mass index were included. Hemostatic markers (fibrin lysability, fibrinogen, coagulation factor XIII, plasminogen, plasminogen activator inhibitor 1 [PAI-1], plasmin inhibitor, thrombin activatable fibrinolysis inhibitor (TAFI), D-dimer), C-reactive protein (CRP), body mass index, waist-to-hip ratio, CFM determined by Dual-energy X-ray absorptiometry scan, and sex hormones (testosterone estradiol, and sex hormone binding globulin) were determined. Results TAFI and CRP were higher in women with PCOS, than controls. In women with PCOS, fibrin lysability correlated with CFM, waist-to-hip ratio, CRP, fibrinogen, and all hemostatic variables (P <= .004) except TAFI and D-dimer. CFM correlated with fibrinogen, CRP, coagulation factor XIII, waist-to-hip ratio, plasminogen, PAI-1, plasmin inhibitor, and TAFI (P < .02). In controls, fibrin lysability correlated with CFM, fibrinogen, coagulation factor XIII, and plasmin inhibitor (P <= .02). CFM correlated with PAI-1, plasmin inhibitor, coagulation factor XIII, fibrinogen, and CRP (P <= .05). Stepwise regression analysis revealed that fibrin lysability was associated with CFM, fibrinogen and CRP in women with PCOS (r(2) = .46, P <= .001), but only with CFM in controls (r(2) = .28, P < .001). Conclusions Fibrin lysability was comparable in women with PCOS and controls. Fibrin lysability was associated with CFM and hyper-inflammation in women with PCOS, but only with CFM in controls. These findings suggest that obese women with PCOS and augmented inflammation could have an increased risk of cardiovascular disease.
- 1 July 2020
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery
- Vol. 78 (7) , 1183-1189
Orthognathic Surgery-Induced Fibrinolytic Shutdown Is Amplified by Tranexamic Acid
- 1 July 2020
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery
- Vol. 78 (7) , 1183-1189
Orthognathic Surgery-Induced Fibrinolytic Shutdown Is Amplified by Tranexamic Acid
- 26 January 2020
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 18 (4) , 876-884
Contact activation‐induced complex formation between complement factor H and coagulation factor XIIa
- 26 January 2020
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 18 (4) , 876-884
Contact activation‐induced complex formation between complement factor H and coagulation factor XIIa
- 1 October 2019
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 40 (Supplement)
P6184Association of coronary plaque characteristics and the translesional gradient by FFRct in asymptomatic patients with newly diagnosed type-2 diabetes mellitus
Coronary CT angiography (CCTA) derived fractional flow reserve (FFRct) is increasingly for decision-making in patients with stable chest pain. The relation between vessel specific plaque characteristics and the translesional gradient by FFRct in patients with type-2 diabetes mellitus (T2DM) is not fully explored. To examine the association between vessel specific plaque characteristics as determined by CCTA and the translesional gradient as assessed by FFRct in asymptomatic patients with newly diagnosed T2DM. Total plaque volume and the volumes of calcified plaque (CP), low-density noncalcified plaque (LD-NCP) and non-LD-NCP were assessed on a per-vessel basis by quantitative plaque analysis using Autoplaque. Irregularities of the vessel wall giving a vessel-specific total plaque volume 1.1. Spotty calcification was defined as calcifications comprising 3), ΔFFRct ≥0.06 vs. ΔFFRct 0.05. The vessel-specific CP volume, median (IQR), was higher in vessels with ΔFFRct ≥0.06 vs. ΔFFRct <0.06: 51.9 (20.5–85.4) vs. 13.5 (4.1–68.5), p=0.015. Adverse plaque characteristics ΔFFRct ≥0.06 vs. ΔFFRct <0.06, were, n (%): positive remodeling, 21 (95%) vs. 34 (97%) and spotty calcification, 9 (41%) vs. 14 (40%). The relative distribution of vessel specific plaque components according to ΔFFRct is illustrated in the Figure. In asymptomatic patients with newly diagnosed and well-controlled T2DM, the occurrence of high-risk coronary plaque features was frequently observed. The applied translesional gradient by FFRct was not predictive of adverse coronary plaque characteristics. The Danish Diabetes Academy supported by the Novo Nordisk Foundation; University of Southern DenmarkCenter Southwest, Denmark
- 1 October 2019
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 40 (Supplement)
P6184Association of coronary plaque characteristics and the translesional gradient by FFRct in asymptomatic patients with newly diagnosed type-2 diabetes mellitus
Coronary CT angiography (CCTA) derived fractional flow reserve (FFRct) is increasingly for decision-making in patients with stable chest pain. The relation between vessel specific plaque characteristics and the translesional gradient by FFRct in patients with type-2 diabetes mellitus (T2DM) is not fully explored. To examine the association between vessel specific plaque characteristics as determined by CCTA and the translesional gradient as assessed by FFRct in asymptomatic patients with newly diagnosed T2DM. Total plaque volume and the volumes of calcified plaque (CP), low-density noncalcified plaque (LD-NCP) and non-LD-NCP were assessed on a per-vessel basis by quantitative plaque analysis using Autoplaque. Irregularities of the vessel wall giving a vessel-specific total plaque volume 1.1. Spotty calcification was defined as calcifications comprising 3), ΔFFRct ≥0.06 vs. ΔFFRct 0.05. The vessel-specific CP volume, median (IQR), was higher in vessels with ΔFFRct ≥0.06 vs. ΔFFRct <0.06: 51.9 (20.5–85.4) vs. 13.5 (4.1–68.5), p=0.015. Adverse plaque characteristics ΔFFRct ≥0.06 vs. ΔFFRct <0.06, were, n (%): positive remodeling, 21 (95%) vs. 34 (97%) and spotty calcification, 9 (41%) vs. 14 (40%). The relative distribution of vessel specific plaque components according to ΔFFRct is illustrated in the Figure. In asymptomatic patients with newly diagnosed and well-controlled T2DM, the occurrence of high-risk coronary plaque features was frequently observed. The applied translesional gradient by FFRct was not predictive of adverse coronary plaque characteristics. The Danish Diabetes Academy supported by the Novo Nordisk Foundation; University of Southern DenmarkCenter Southwest, Denmark
- 26 March 2019
- Published by Springer Nature in European Radiology
- Vol. 29 (11) , 5920-5931
Carotid plaque composition by CT angiography in asymptomatic subjects: a head-to-head comparison to ultrasound
To describe carotid plaque composition by computed tomography angiography (CTA) in asymptomatic subjects and to compare this to carotid plaque assessment by ultrasound, coronary plaques by coronary CTA, and inflammatory biomarkers in plasma.
- 26 March 2019
- Published by Springer Nature in European Radiology
- Vol. 29 (11) , 5920-5931
Carotid plaque composition by CT angiography in asymptomatic subjects: a head-to-head comparison to ultrasound
To describe carotid plaque composition by computed tomography angiography (CTA) in asymptomatic subjects and to compare this to carotid plaque assessment by ultrasound, coronary plaques by coronary CTA, and inflammatory biomarkers in plasma.
- 1 February 2019
- Published by Elsevier in Thrombosis Research
- Vol. 174, 129-136
Sex difference in fibrin clot lysability: Association with coronary plaque composition
- 1 February 2019
- Published by Elsevier in Thrombosis Research
- Vol. 174, 129-136
Sex difference in fibrin clot lysability: Association with coronary plaque composition
- 28 September 2018
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 44 (08) , 734-746
Anabolic Androgenic Steroid Abuse: The Effects on Thrombosis Risk, Coagulation, and Fibrinolysis
Anabolic androgenic steroid (AAS) abuse surged during the 1980s and is seen in approximately 1 in 20 of all males today. A wide spectrum of AAS compounds and abuse regimens are applied and AAS abuse has been associated with an unfavorable cardiovascular profile. The aim of this review is to critique the collected data concerning effects of AAS abuse on thrombosis risk through presentation of condensed evidence from studies investigating AAS-induced changes in coagulation, fibrinolysis, and cardiovascular risk markers. AAS abuse inflicts a procoagulant distribution of cardiovascular risk markers including dyslipidemia and atherosclerosis proneness. AAS abuse overall stimulates synthesis of coagulation factors, inhibitors, and fibrinolytic proteins resulting in both increased global coagulation and stimulation of fibrinolysis. Overall, supported by many case reports and some epidemiological studies, AAS abuse is associated with an increased risk of thrombosis. However, to provide clear evidence for a causal relationship between AAS abuse and thrombosis risk, future studies need to address a range of potential biases, insufficient methodology, and other shortcomings of the current literature as highlighted in this review.
- 28 September 2018
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 44 (08) , 734-746
Anabolic Androgenic Steroid Abuse: The Effects on Thrombosis Risk, Coagulation, and Fibrinolysis
Anabolic androgenic steroid (AAS) abuse surged during the 1980s and is seen in approximately 1 in 20 of all males today. A wide spectrum of AAS compounds and abuse regimens are applied and AAS abuse has been associated with an unfavorable cardiovascular profile. The aim of this review is to critique the collected data concerning effects of AAS abuse on thrombosis risk through presentation of condensed evidence from studies investigating AAS-induced changes in coagulation, fibrinolysis, and cardiovascular risk markers. AAS abuse inflicts a procoagulant distribution of cardiovascular risk markers including dyslipidemia and atherosclerosis proneness. AAS abuse overall stimulates synthesis of coagulation factors, inhibitors, and fibrinolytic proteins resulting in both increased global coagulation and stimulation of fibrinolysis. Overall, supported by many case reports and some epidemiological studies, AAS abuse is associated with an increased risk of thrombosis. However, to provide clear evidence for a causal relationship between AAS abuse and thrombosis risk, future studies need to address a range of potential biases, insufficient methodology, and other shortcomings of the current literature as highlighted in this review.
- 22 June 2018
- Published by Wiley in Diabetic Medicine
- Vol. 35 (11) , 1588-1595
Sex differences in coronary plaque composition evaluated by coronary computed tomography angiography in newly diagnosed Type 2 diabetes: association with low‐grade inflammation
Aim: To determine differences in coronary plaque composition and inflammatory biomarkers between men and women with newly diagnosed Type 2 diabetes without known cardiovascular disease.Methods: A total of 88 people with newly diagnosed (0.05). The median (quartiles) serum levels of fibrinogen [10.9 (9.8–12.6) μmol/l vs 9.7 (8.8–10.9) μmol/l], fibrin d‐dimer [0.3 (0.2–0.4) mg/l vs 0.27 (0.2–0.4) mg/l] and C‐reactive protein [3.1 (1.1–5.2) mg/l vs (0.8–2.6) 1.6 mg/l] were significantly higher in women (all PP3 vs 61.1 (7.6–239.9) mm3] and absolute calcified plaque volume [33.5 (8.3–148.3) mm3 vs 4.7 (0.9–17.3) mm3] were higher in men (both PP<0.05].Conclusions: In people with newly diagnosed Type 2 diabetes, women had lower absolute coronary plaque volumes but a more unfavourable plaque composition and enhanced systemic inflammation compared with men.
- 22 June 2018
- Published by Wiley in Diabetic Medicine
- Vol. 35 (11) , 1588-1595
Sex differences in coronary plaque composition evaluated by coronary computed tomography angiography in newly diagnosed Type 2 diabetes: association with low‐grade inflammation
Aim: To determine differences in coronary plaque composition and inflammatory biomarkers between men and women with newly diagnosed Type 2 diabetes without known cardiovascular disease.Methods: A total of 88 people with newly diagnosed (0.05). The median (quartiles) serum levels of fibrinogen [10.9 (9.8–12.6) μmol/l vs 9.7 (8.8–10.9) μmol/l], fibrin d‐dimer [0.3 (0.2–0.4) mg/l vs 0.27 (0.2–0.4) mg/l] and C‐reactive protein [3.1 (1.1–5.2) mg/l vs (0.8–2.6) 1.6 mg/l] were significantly higher in women (all PP3 vs 61.1 (7.6–239.9) mm3] and absolute calcified plaque volume [33.5 (8.3–148.3) mm3 vs 4.7 (0.9–17.3) mm3] were higher in men (both PP<0.05].Conclusions: In people with newly diagnosed Type 2 diabetes, women had lower absolute coronary plaque volumes but a more unfavourable plaque composition and enhanced systemic inflammation compared with men.
- 31 May 2018
- Published by SAGE Publications in Lupus
- Vol. 27 (9) , 1446-1454
Revisiting the Phadia/EliA cut-off values for anticardiolipin and anti-β2-glycoprotein I antibodies: a systematic evaluation according to the guidelines
Background: Phadia/EliA fluorescence enzyme immunoassays are widely used automated assays for anticardiolipin (aCL) and anti-β2-glycoprotein I (aβ2GPI) antibodies. To date, cut-off values for these assays have not been evaluated systematically and the evidence behind manufacturer’s recommended cut-off values is not clear. Objective: To determine Phadia/EliA cut-off values for antiphospholipid antibodies (aPL) according to the procedures suggested by guidelines. Methods: A total of 266 blood donors (135 females and 131 males) were included. The pre-handling and analysis of the samples were performed according to the International Society on Thrombosis and Hemostasis (ISTH) guideline for solid phase aPL assays. Cut-off values and corresponding 90% confidence intervals (CI) for each antibody were established and outliers were handled according to the Clinical and Laboratory Standards Institute (CLSI) guideline for reference intervals. Samples from 377 consecutive patients, referred to our thrombophilia center with evidence of thrombosis or pregnancy morbidity were included for aPL testing. Results: The in-house 99th (97.5th) percentile cut-off values were 11 (8.7), 12 (6.9) 8.5 (5.0) AU/mL for aβ2GPI IgG, IgM and IgA, and 21 (13) GPL-U/mL and 41 (25) MPL-U/mL for aCL IgG and IgM, respectively. The prevalence of positive results (%) defined by these cut-off values in patients with evidence of thrombosis or pregnancy morbidity was 9.5 (12.2), 1.6 (2.9), and 7.0 (9.9), and 0.8 (3.8) for aβ2GPI IgG, IgM, and aCL IgG and IgM respectively. The use of in-house 99th percentile cut-off values compared to the manufacturer suggested cut-off values resulted in 1 and 39 fewer samples for aβ2GPI and aCL to be classified as positive for aPL, respectively. Conclusions: We present Phadia/EliA cut-off values with 90% CI for aPL determined systematically according to the ISTH and CLSI guidelines. These values are different from values previously determined, suggesting variation of aPLs in different populations. Our findings indicate the need for each laboratory to determine/validate assay specific cut-off values for aPL.
- 31 May 2018
- Published by SAGE Publications in Lupus
- Vol. 27 (9) , 1446-1454
Revisiting the Phadia/EliA cut-off values for anticardiolipin and anti-β2-glycoprotein I antibodies: a systematic evaluation according to the guidelines
Background: Phadia/EliA fluorescence enzyme immunoassays are widely used automated assays for anticardiolipin (aCL) and anti-β2-glycoprotein I (aβ2GPI) antibodies. To date, cut-off values for these assays have not been evaluated systematically and the evidence behind manufacturer’s recommended cut-off values is not clear. Objective: To determine Phadia/EliA cut-off values for antiphospholipid antibodies (aPL) according to the procedures suggested by guidelines. Methods: A total of 266 blood donors (135 females and 131 males) were included. The pre-handling and analysis of the samples were performed according to the International Society on Thrombosis and Hemostasis (ISTH) guideline for solid phase aPL assays. Cut-off values and corresponding 90% confidence intervals (CI) for each antibody were established and outliers were handled according to the Clinical and Laboratory Standards Institute (CLSI) guideline for reference intervals. Samples from 377 consecutive patients, referred to our thrombophilia center with evidence of thrombosis or pregnancy morbidity were included for aPL testing. Results: The in-house 99th (97.5th) percentile cut-off values were 11 (8.7), 12 (6.9) 8.5 (5.0) AU/mL for aβ2GPI IgG, IgM and IgA, and 21 (13) GPL-U/mL and 41 (25) MPL-U/mL for aCL IgG and IgM, respectively. The prevalence of positive results (%) defined by these cut-off values in patients with evidence of thrombosis or pregnancy morbidity was 9.5 (12.2), 1.6 (2.9), and 7.0 (9.9), and 0.8 (3.8) for aβ2GPI IgG, IgM, and aCL IgG and IgM respectively. The use of in-house 99th percentile cut-off values compared to the manufacturer suggested cut-off values resulted in 1 and 39 fewer samples for aβ2GPI and aCL to be classified as positive for aPL, respectively. Conclusions: We present Phadia/EliA cut-off values with 90% CI for aPL determined systematically according to the ISTH and CLSI guidelines. These values are different from values previously determined, suggesting variation of aPLs in different populations. Our findings indicate the need for each laboratory to determine/validate assay specific cut-off values for aPL.
- Open Access
- 13 February 2018
- Published by Springer Nature in Biology of Sex Differences
- Vol. 9 (1) , 1-7
Sex difference in clot lysability and association to coronary artery calcification
Incidence and prevalence of cardiovascular disease (CVD) differ between sexes, and women experience CVD later than men. Changes in fibrin clot lysability are associated with CVD, and the present study addresses sex differences in fibrin clot lysability in asymptomatic middle-aged individuals and the relation to coronary artery calcification (CAC). Participants free of morbidities and medication, N = 163, were randomly chosen from a national registry among citizens, 50 or 60 years of age, and were followed for 5 years. CAC was determined by the Agatston (Ag) score both at baseline and at follow-up. Based on the changes in Ag, the population was divided into two groups: ΔAg = 0 U or ΔAg > 0 U. Fibrin clot analyses were based on turbidimetric methods. At baseline, 116 women and 97 men were included; 84 women and 79 men completed the 5-year follow-up (77%). Independently of covariates, women with ΔAg > 0 had reduced mean (SD) fibrin lysability at follow-up, 40.2% (15.9), both in comparison to baseline, 47.8% (20.4), p = 0.001, to women with ΔAg = 0 U, 51.2% (24.5), p = 0.028, and to men with ΔAg > 0 U, 54.4% (21.0), p = 0.002. Fibrin clot lysability changes over time with considerable sex differences. Women with progression of CAC have reduced fibrin clot lysability compared to men, indicating a sex-specific association between morphological vessel wall changes and fibrin clot lysability.
- 13 February 2018
- Published by Springer Nature in Biology of Sex Differences
- Vol. 9 (1) , 1-7
Open AccessSex difference in clot lysability and association to coronary artery calcification
Incidence and prevalence of cardiovascular disease (CVD) differ between sexes, and women experience CVD later than men. Changes in fibrin clot lysability are associated with CVD, and the present study addresses sex differences in fibrin clot lysability in asymptomatic middle-aged individuals and the relation to coronary artery calcification (CAC). Participants free of morbidities and medication, N = 163, were randomly chosen from a national registry among citizens, 50 or 60 years of age, and were followed for 5 years. CAC was determined by the Agatston (Ag) score both at baseline and at follow-up. Based on the changes in Ag, the population was divided into two groups: ΔAg = 0 U or ΔAg > 0 U. Fibrin clot analyses were based on turbidimetric methods. At baseline, 116 women and 97 men were included; 84 women and 79 men completed the 5-year follow-up (77%). Independently of covariates, women with ΔAg > 0 had reduced mean (SD) fibrin lysability at follow-up, 40.2% (15.9), both in comparison to baseline, 47.8% (20.4), p = 0.001, to women with ΔAg = 0 U, 51.2% (24.5), p = 0.028, and to men with ΔAg > 0 U, 54.4% (21.0), p = 0.002. Fibrin clot lysability changes over time with considerable sex differences. Women with progression of CAC have reduced fibrin clot lysability compared to men, indicating a sex-specific association between morphological vessel wall changes and fibrin clot lysability.